ACHIEVE LIFE SCIENCES, INC.
ACHIEVE LIFE SCIENCES, INC. (ACHV): 11 pipeline candidates · ~13 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.9 months
D/E 2.10 · 0% dilution
Lead: Approved
11 candidates
N/A
N/A
A transparent, data-derived signal for ACHIEVE LIFE SCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$571.8M
Cash
$28.1M
Quarterly Burn
$6.9M
Runway
12.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| acetazolamide | Approved |
| colistimethate | Approved |
| custirsen | Phase 3 |
| Cytisine | Phase 4 |
| cytisinicline | Phase 4 |
| diphenhydramine | Approved |
| foscarnet | Approved |
| ibandronate | Approved |
| isoproterenol | Approved |
| palonosetron | Approved |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$56.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,409,428 | $13.0M |
| franklin resources inc | 4,369,193 | $12.8M |
| simplify asset management inc. | 1,184,512 | $3.5M |
| millennium management llc | 1,077,338 | $3.2M |
| marshall wace, llp | 1,019,281 | $3.0M |
| raymond james financial inc | 641,925 | $1.9M |
| geode capital management, llc | 622,785 | $1.8M |
| two sigma investments, lp | 588,551 | $1.7M |
| susquehanna international group, llp | 510,883 | $1.5M |
| kvp capital advisors, lp | 462,355 | $1.4M |
Showing top 10 of 79 institutional holders of ACHIEVE LIFE SCIENCES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ACHIEVE LIFE SCIENCES, INC.'s pipeline?
ACHIEVE LIFE SCIENCES, INC. (ACHV) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACHIEVE LIFE SCIENCES, INC.'s lead drug candidate?
ACHIEVE LIFE SCIENCES, INC.'s most advanced tracked candidate is acetazolamide (Approved) for INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rap.
What is ACHIEVE LIFE SCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACHIEVE LIFE SCIENCES, INC. has approximately 12.9 months of cash runway.
What is ACHIEVE LIFE SCIENCES, INC.'s market capitalization?
ACHIEVE LIFE SCIENCES, INC.'s market capitalization is approximately $571.8M.
Who is the CEO of ACHIEVE LIFE SCIENCES, INC.?
Dr. Andrew D. Goldberg M.D. is the chief executive officer of ACHIEVE LIFE SCIENCES, INC. (ACHV).
Get the full picture on ACHIEVE LIFE SCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.